Evonile Pharma Approves ₹9,000 Million Rights Issue

Evonile Pharma Limited (formerly Novartis India Limited) announced its Board of Directors has approved a Rights Issue to raise funds up to ₹9,000 million (₹900 Crore). The funds will be raised through the issuance and allotment of partly paid-up equity shares. The Board also approved the constitution of a Rights Issue Committee to finalize the terms and conditions, including issue size, price, and record date. Additionally, the company approved a postal ballot notice for shareholder approval and the launch of its new corporate website, www.evonilepharma.com. The meeting was held on October 08, 2026.